. A 57-year-old man was diagnosed as having thalassemia intermedia at the age of 3 years (genotype CD39/IVS 1-6). He received sporadic blood transfusions since childhood and was submitted to splenectomy at the age of 15 years due to giant splenomegaly. Over the years, he developed hemocromatosis secondary to iron overload and was infected by hepatitis C, which was most probably transmitted via blood transfusion before 1990. In April 2018, during a periodical clinical follow-up, an abdominal ultrasound examination revealed multiple lesions in the right hepatic lobe, subsequently confirmed by contrast-enhanced/computed tomography (ce-CT). The patient underwent biopsy which resulted positive for welldifferentiated hepatocellular carcinoma (HCC). He received sorafenib until September 2018 when treatment was discontinued due to the onset of cutaneous toxicity and evidence of progressive disease shown by ce-CT. He was enrolled for a loco-regional treatment of the hepatic lesion through radioembolization with 90 Y-microspheres. Before the radioembolization procedure, he was submitted to positron emission tomography/CT (PET/CT) with 18 F-choline. (A) PET maximum intensity projection showed increased tracer uptake in the hepatic dome (black arrow) and diffuse hyperactivity in the axial and appendicular skeleton (black countered arrows). The corresponding fused PET/CT (B) and ce-CT (C) axial slices demonstrated multiple lesions, with a necrotic peripheral component, in the right hepatic lobe, characterized by intense 18 F-choline incorporation with much higher uptake values (SUV max : 17.0, SUV mean : 6.1) than those calculated in the normal liver parenchyma (SUV max : 7.7, SUV mean : 5.7). Thalassemia intermedia is a rare inherited genetic disease, characterized by a wide spectrum of clinical manifestations (2) . Iron overload due to the chronic hemolysis and periodic blood transfusion leads to severe complications, especially at cardiac and hepatic level. Since recent improvements in treatment of thalassemia have led to a significantly prolonged survival, HCC, most probable related to the frequent association of hepatitis C virusinfection and hemocromatosis in thalassemic patients, has emerged as a relatively new complication in long-term survivors (3) . Although conventional radiological imaging through CT and magnetic resonance imaging represents the first-line approach for HCC diagnosis, PET/CT with 18 F-choline has been introduced as a useful tool for the imaging of HCC, especially before and after loco-regional treatments (4, 5) . To the best of our knowledge, this is the first report describing the pattern of 18 F-choline uptake in a thalassemic patient. It has to be pointed out that diffuse skeletal uptake of 18 F-fluciclovine has been recently described in a thalassemic patient affected by prostate cancer with suspicion of bone metastasis (6) . Although 18 F-fluciclovine and 18 F-choline represent different molecular probes in oncology, since the former reflects the upregulation of transmembrane aminoacids transport (7) while the latter is a biomarker of phospholid synthesis (8) , increased uptake of both these 2 tracers in the bone marrow of thalassemic patients are most probably due to hematopoiesis stimulation induced by chronic hemolysis.
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